

Amendments to the specification:

Amend the first full paragraph on page 3 as indicated:

In the specification of [[the]] International Patent Application No. WO 03/051362, different polymorph forms of clopidogrel hydrogensulfate are obtained by recrystallizing clopidogrel hydrogensulfate from different solvents or by the precipitation with anti-solvents from its solutions.

Amend the last paragraph on page 5 as indicated:

International Patent Application WO 03/051362 describes several processes to produce the desired polymorph form 1, but only a few solvents are suggested to be used in these processes. Moreover, these processes result in a mixture of amorphous form and polymorph form 1 in some cases. This is undesirable, because it is preferable to employ handling with the morphologically uniform products in connection with further handling of the products the technology.

Amend the paragraph bridging pages 13-14 as indicated:

~~Great advantage~~ A significant benefit of the present invention is that the ~~used~~ solvents used in the preparation of the polymorph form 1 can be chosen from more different types of solvents[[[,] than [[it]] is known from the state of the art. Moreover, [[and]] the chosen solvents can be adapted easily to ~~the used~~ conventional technology for the production of polymorph form 1 of clopidogrel hydrogensulfate in a reproducible way. For example, use of dichloromethane as "A" type solvent is very advantageous because it can be used for the extraction of clopidogrel base obtained when setting it free from its camphorsulfonic acid salt. According to the present invention, clopidogrel hydrogensulfate can be obtained as polymorph form 1 in one step without exchange of the solvent. Thus, the required time and costs of chemicals are reduced as well.